A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I trial tests the safety, side effects, and best dose of ASTX727 and filgrastim for the treatment of children with high risk acute myeloid leukemia that has come back after a period of improvement (recurrent) or that does not respond to treatment (refractory) who have undergone allogenic hematopoietic stem cell transplantation. ASTX727 is a combination of cedazuridine and decitabine. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Filgrastim stimulates the production of neutrophils (a type of white blood cell) which can help to prevent infection. Giving ATSX727 and filgrastim may be safe and tolerable in treating children with high risk, recurrent or refractory acute myeloid leukemia who have undergone allogenic hematopoietic stem cell transplantation.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Dzieci do 21. roku życia.
- •Dzieci z ostrym szpiczakiem szpiku, który powrócił po leczeniu lub nie reaguje na leczenie, u których przeprowadzono przeszczep komórek macierzystych.
- •Dzieci, u których choroba jest w fazie remisji przed przeszczepem.
- •Dzieci, które planują pobranie próbki szpiku kostnego do badania przed przeszczepem.
Simplified criteria — AI translation
Trial details
- Maximum age
- 21 Years
- Last updated (source)
- July 7, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (8)
Children's Hospital of Alabama
Birmingham, United States
Riley Hospital for Children
Indianapolis, United States
C S Mott Children's Hospital
Ann Arbor, United States
University of Minnesota/Masonic Cancer Center
Minneapolis, United States
Memorial Sloan Kettering Cancer Center
New York, United States
Children's Hospital of Philadelphia
Philadelphia, United States
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, United States
Saint Jude Children's Research Hospital
Memphis, United States
Trial contact
Site Public Contact
Girish Dhall
PRINCIPAL_INVESTIGATOR
Site Public Contact
Brian D. Weiss
PRINCIPAL_INVESTIGATOR
Site Public Contact
Rajen Mody
PRINCIPAL_INVESTIGATOR
Site Public Contact
Robin L. Williams
PRINCIPAL_INVESTIGATOR
Site Public Contact
Maria Luisa Sulis
PRINCIPAL_INVESTIGATOR
Site Public Contact
Sarah K. Tasian
PRINCIPAL_INVESTIGATOR
Site Public Contact
Archana Ramgopal
PRINCIPAL_INVESTIGATOR
Site Public Contact
Jessica Gartrell
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/8/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.